X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (34) 34
index medicus (24) 24
humans (23) 23
animals (20) 20
testosterone (19) 19
article (14) 14
middle aged (14) 14
androgens (13) 13
rats (13) 13
endocrinology & metabolism (12) 12
oncology (12) 12
mice (11) 11
aged (10) 10
female (10) 10
prostate cancer (10) 10
dihydrotestosterone (9) 9
cancer (8) 8
castration (8) 8
testosterone - blood (8) 8
aging (7) 7
prostate (7) 7
prostatic neoplasms - drug therapy (7) 7
abiraterone (6) 6
abridged index medicus (6) 6
adult (6) 6
arcuate nucleus (6) 6
gene expression (6) 6
in situ hybridization (6) 6
insulin - blood (6) 6
older men (6) 6
progression (6) 6
prostate - drug effects (6) 6
rats, inbred bn (6) 6
aging - physiology (5) 5
analysis (5) 5
body composition - drug effects (5) 5
dutasteride (5) 5
insulin (5) 5
metastases (5) 5
prostate-specific antigen - blood (5) 5
prostatic neoplasms - pathology (5) 5
therapy (5) 5
abiraterone acetate (4) 4
aged, 80 and over (4) 4
androgen receptor (4) 4
diabetes (4) 4
dihydrotestosterone - metabolism (4) 4
dopamine (4) 4
dose-response relationship, drug (4) 4
double-blind method (4) 4
expression (4) 4
fasting (4) 4
leptin (4) 4
men (4) 4
mice, inbred c57bl (4) 4
neurons (4) 4
neurosciences (4) 4
orchiectomy (4) 4
patients (4) 4
physiological aspects (4) 4
prostate - metabolism (4) 4
prostatic neoplasms - blood (4) 4
rats, sprague-dawley (4) 4
receptors, androgen - genetics (4) 4
research (4) 4
resistance (4) 4
risk (4) 4
serum testosterone (4) 4
steroids (4) 4
survival (4) 4
acetate (3) 3
aging - genetics (3) 3
androgen antagonists - therapeutic use (3) 3
behavior (3) 3
biochemistry & molecular biology (3) 3
blood glucose - analysis (3) 3
body weight (3) 3
body weight - drug effects (3) 3
body-composition (3) 3
brain - metabolism (3) 3
cardiovascular diseases (3) 3
cardiovascular diseases - prevention & control (3) 3
care and treatment (3) 3
dehydroepiandrosterone (3) 3
diabetes mellitus, type 2 - complications (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
diet (3) 3
dihydrotestosterone - blood (3) 3
drug therapy, combination (3) 3
enzalutamide (3) 3
estradiol (3) 3
estradiol - blood (3) 3
experimental design (3) 3
fatty acids (3) 3
feeding behavior - physiology (3) 3
finasteride (3) 3
follow-up studies (3) 3
food-intake (3) 3
further section (3) 3
gene-expression (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European urology, ISSN 0302-2838, 06/2019
Androgen deprivation therapy improves the survival of castration-resistant prostate cancer (CRPC) patients, yet ultimately fails with debilitating side... 
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2169 - 2176
Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or... 
THERAPY | ANTIANDROGEN | ONCOLOGY | RESISTANCE | PHASE-II | RADICAL PROSTATECTOMY | INCREASED SURVIVAL | CANCER | CHEMOTHERAPY | PROGRESSION | ABIRATERONE | Neoplasm, Residual - pathology | Phenylthiohydantoin - adverse effects | Prostatic Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Combined Modality Therapy | Neoplasm, Residual - blood | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Phenylthiohydantoin - administration & dosage | Receptors, Androgen - genetics | Leuprolide - administration & dosage | Neoadjuvant Therapy - adverse effects | Prostatic Neoplasms - blood | Prostatectomy | Aged | Neoplasm, Residual - chemically induced | Dutasteride - administration & dosage | Prostatic Neoplasms - drug therapy | Therapy | Risk groups | Health risks | Minimal residual disease | Patients | Anticancer properties | Testosterone | Signaling | Dihydrotestosterone | Androgens | Flutamide | Experimental design | Luteinizing hormone | Luteinizing hormone-releasing hormone | Antitumor activity | Prostate cancer | Prostate | Cancer | dutasteride | neoadjuvant | NEW MOLECULAR TARGETS | THERAPEUTICS: Cellular responses to anticancer drugs | CL01 PHASE I – III CLINICAL TRIALS: Phase I–III Trials_Genitourinary cancers: prostate | ET02 MECHANISMS OF DRUG ACTION | enzalutamide
Journal Article
Journal Article
Obesity, ISSN 1930-7381, 12/2018, Volume 26, Issue 12, pp. 1898 - 1904
Objective This study aimed to determine whether a relationship was evident between gliosis in the mediobasal hypothalamus (MBH) and plasma testosterone... 
LEPTIN | METABOLIC SYNDROME | OBESITY | HOMEOSTASIS | NUTRITION & DIETETICS | INSULIN-RESISTANCE | PROSTATE-CANCER | ENDOCRINOLOGY & METABOLISM | RISK | MICE | WEIGHT | PATHOPHYSIOLOGY | men, obesity | gliosis | testosterone | mediobasal hypothalamus
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 426 - 439
Purpose: Tumor androgens in castration resistant prostate cancer (CRPC) reflect de novo intra-tumoral synthesis or adrenal androgens. We used C.B.-17 SCID mice... 
VENTRAL PROSTATE | 3-BETA-HYDROXYSTEROID DEHYDROGENASE | DIHYDROTESTOSTERONE LEVELS | MALE-RAT | ONCOLOGY | TESTOSTERONE | GENE-EXPRESSION | ABIRATERONE ACETATE | RECEPTOR | SERUM | GUINEA-PIG
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2015, Volume 92, Issue 2, pp. 236 - 243
Purpose Optimizing androgen suppression may provide better control of localized prostate cancer (PCa). Numerous trials have supported the benefit of combining... 
Radiology | Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | SURVIVAL | DEPRIVATION THERAPY | ONCOLOGY | GROUP PROTOCOL 92-02 | TOXICITY | RADIOTHERAPY | DNA-REPAIR | SUPPRESSION | ACETATE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | NEOADJUVANT | Prostatic Neoplasms - chemistry | Prostatic Neoplasms - radiotherapy | Prospective Studies | Humans | Male | Prostate - pathology | Time Factors | Androgens - analysis | Prostatic Neoplasms - blood | Goserelin - adverse effects | Goserelin - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Endoscopic Ultrasound-Guided Fine Needle Aspiration | Prostatic Neoplasms - drug therapy | Radiotherapy Dosage | Prostatic Neoplasms - pathology | Prednisone - adverse effects | Androstenes - adverse effects | Androstenes - analysis | Androstenes - therapeutic use | Prostate-Specific Antigen - blood | Neoadjuvant Therapy - adverse effects | Neoadjuvant Therapy - methods | Leuprolide - therapeutic use | Androgen Antagonists - therapeutic use | Leuprolide - adverse effects | Androgen Antagonists - adverse effects | Prednisone - therapeutic use | Pituitary hormones | Safety and security measures | Radiation | Glycoproteins | Hormones, Sex | Radiotherapy | Prostate cancer | Index Medicus | PROSTATE | LUTEINIZING HORMONE | PATIENTS | LYMPHOPENIA | EXTERNAL BEAM RADIATION THERAPY | NEOPLASMS | SAFETY | FATIGUE | BIOPSY | POPULATIONS | ANTIGENS | MASS SPECTROSCOPY | LIBERINS | MEN | RADIOLOGY AND NUCLEAR MEDICINE | OPTIMIZATION | ANDROGENS | HYPERTENSION | HAZARDS
Journal Article